Current laboratory parameters, including anti-dsDNA, C3, proteinuria, and eGFR, are not reliable for early diagnosis and monitoring of treatment responses, and a renal biopsy remains the gold standard for the diagnosis and prognosis of LN. This evidence concerns the gene C3 and lobular neoplasia.